Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HMGCR | P04035 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | BHMT | Q93088 | 3/20 | 0.41 |
| ▸ | CPT2 | P23786 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 2/20 | 0.34 |
| ▸ | GABRD | O14764 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4303264 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MAPTPTGS1KDM4EHMGCR | |
| SCHEMBL27759274 | 0.84 | HMGCR (0.42) | ALDH1A1MAPTPTGS1KDM4EHMGCR | |
| SCHEMBL25329387 | 0.84 | PTGS1 (0.48) | ALDH1A1MAPTPTGS1KDM4EHMGCR | |
| SCHEMBL12655752 | 0.84 | PTGS1 (0.48) | ALDH1A1MAPTPTGS1KDM4EHMGCR | |
| SCHEMBL21447986 | 0.83 | KDM4E (0.52) | ALDH1A1MAPTPTGS1KDM4EHMGCR | |
| SCHEMBL20960490 | 0.80 | PTGS1 (0.54) | ALDH1A1MAPTPTGS1KDM4EGABRP | |
| SCHEMBL6130129 | 0.79 | ALDH1A1 (0.48) | ALDH1A1MAPTPTGS1KDM4EHMGCR | |
| SCHEMBL6130132 | 0.79 | ALDH1A1 (0.48) | ALDH1A1MAPTPTGS1KDM4EHMGCR | |
| SCHEMBL4956090 | 0.78 | PTGS1 (0.52) | ALDH1A1MAPTPTGS1KDM4ESLC7A5 | |
| SCHEMBL4851556 | 0.78 | PTGS1 (0.52) | ALDH1A1MAPTPTGS1KDM4ESLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118302524-A | High molecular weight modified dsRNA compositions | 纳诺索尔公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2020009231-A1 | NOVEL LIPASE CAPABLE OF DECOMPOSING OIL OR FAT CONTAINING TRANS-FATTY ACID | 国立大学法人名古屋大学 | 2020-01-09 | — | — | WO | disclosed |
| US-20130096055-A1 | LONG-ACTING Y2 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2013-04-18 | — | — | US | disclosed |
| US-20130096055-A1 | LONG-ACTING Y2 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2013-04-18 | — | — | US | disclosed |
| US-20130040877-A1 | LONG-ACTING Y2 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2013-02-14 | — | — | US | disclosed |
| US-20130040877-A1 | LONG-ACTING Y2 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2013-02-14 | — | — | US | disclosed |
| US-7541195-B2 | Substrate for biomolecule microarray, biomolecule microarray, device and method of promoting interaction, and method of detecting interaction | RIKEN (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20070037155-A1 | Having biomolecule immobilization regions of prescribed shape on a biomolecule microarray, and means by which the interaction of biomolecules is rapidly conducted, the interaction of trace quantities of sample is promoted, and the interaction is detected and analyzed rapidly and with high sensitivity | RIKEN (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-1643248-A1 | SUBSTRATE FOR BIOMOLECULE MICROARRAY, BIOMOLECULE MICROARRAY, DEVICE AND METHOD FOR INTERACTION ACCELERATION, AND INTERACTION DETECTING METHOD | Riken (JP) | 2006-04-05 | — | — | EP | disclosed |
| US-20060046209-A1 | Image forming method | KONICA MINOLTA MEDICAL & GRAPHIC, INC. | 2006-03-02 | — | — | US | disclosed |
| CN-1078279-C | Bleaching process comprising the use of a phenol oxidizing enzyme, a hydrogen peroxide source and an enhancing agent | NOVO CHIMAIDS AS (DK) | 2002-01-23 | — | — | CN | disclosed |
| CN-1161723-A | Bleaching method by use of phenol oxidization enzyme, hydrogen peroxide source and enhancing agent | NOVO NORDISK AS (DK) | 1997-10-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096055-A1 | LONG-ACTING Y2 RECEPTOR AGONISTS | NPY2R, NPY1R, NPY5R | ALDH1A1 4710/4885MAPT 2741/4885PTGS1 855/4885 |
| US-20130040877-A1 | LONG-ACTING Y2 RECEPTOR AGONISTS | NPY2R, NPY1R, NPY5R | ALDH1A1 4829/4885MAPT 3574/4885PTGS1 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.